Immunity to one coronavirus confers cross-immunity to other strains
Current immunological research demonstrates that immunity to one coronavirus can confer cross-reactive cellular and humoral responses to other strains, serving as the biological basis for pan-coronavirus vaccine development.
The retrieved literature consistently supports the premise that immunity to one coronavirus can provide cross-reactive protection against other strains. Studies highlight that conserved epitopes across coronaviruses (such as in the S2 subunit, RBD, and internal proteins) can be targeted to induce cross-reactive T-cell and antibody responses, and that prior exposure to seasonal coronaviruses contributes to cross-protection. Therefore, the claim is supported by the evidence.
Simon V, Floda D, Gleason C, Gonzalez-Reiche AS, Paniz-Mondolfi AE, Sordillo EM, Palese P, van Bakel H. The pandemic gap of respiratory viruses during the COVID-19 pandemic.. 2026. https://doi.org/10.1128/mbio.03376-25
Evidence indicates that prior exposure to seasonal coronaviruses can trigger broad immune responses, resembling trained immunity, that offer temporary cross-protection against other respiratory viruses.
See more details
Naomi R Waterlow, Edwin van Leeuwen, Nicholas G. Davies, Stefan Flasche, Rosalind M Eggo. How immunity from and interaction with seasonal coronaviruses can shape SARS-CoV-2 epidemiology. 2021. https://doi.org/10.1101/2021.05.27.21257032
Mathematical modeling of seasonal human coronaviruses suggests that cross-protection exists and plays a role in shaping susceptibility and epidemiology.
Ikrar T, Muchsin W, Sophian A. Beyond strain-specific immunity: Conserved antigenic targets, emerging platforms, and translational challenges in universal influenza and pan-coronavirus vaccine development.. 2026. https://doi.org/10.1016/j.jviromet.2026.115432
Research highlights conserved epitopes across coronavirus strains as key targets for pan-coronavirus vaccines capable of conferring broad-spectrum protection.
Kubo M. The Role of CD4 T Cell Repertoire and Immune Memory Mechanisms in Vaccination and Infection Immunity.. 2026. https://doi.org/10.1111/imr.70148
Pre-existing cross-reactive CD4+ T cells primed through prior seasonal coronavirus exposure provide robust cross-variant recognition.
Karczmarzyk K, Kęsik-Brodacka M. Challenges and Prospects in the Development of a Universal SARS-CoV-2 Vaccine.. 2026. https://doi.org/10.3390/vaccines14020173
Conserved epitopes within spike and other viral proteins form the foundation for universal coronavirus vaccine strategies designed to elicit cross-neutralizing responses.
Asaad M, Mustafa MO, Al-Haneedi Y, Shalaby L, Shams Eldin R, Mohamedahmed Y, Yassine HM, Abdallah AM, Emara MM. The Feasibility of Developing a Universal SARS-CoV-2 Vaccine.. 2026. https://doi.org/10.3390/vaccines14030259
Evaluation of pan-coronavirus vaccine platforms emphasizes targeting conserved regions like the S2 subunit to achieve cross-strain immunity.
Federico L, Odainic A, Lund KP, Egner IM, Wiese KE, Cornelissen LAHM, Kared H, Stratford R, Kapell S, Malone B, Gheorghe M, Machart P, Siarheyeu R, Tanaka Y, Clancy T, Bendjama K, Munthe LA. Machine Learning–Driven Antigen Selection Reveals Conserved T-Cell Targets for Broad Coronavirus Vaccination. 2026. https://doi.org/10.64898/2026.04.02.716054
Evolutionarily conserved non-spike targets across betacoronaviruses elicit functional, cross-reactive T-cell immunity in humans.
The paper trail · every fact has a biography
Challenge the receipt
Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.
Terms · Privacy · How verdicts work · Dispute this receipt